<DOC>
	<DOCNO>NCT01459016</DOCNO>
	<brief_summary>This study investigate volume , function composition brain use magnetic resonance imaging ( MRI ) positron emission tomography ( PET ) scan technology participant memory complaint early sign Alzheimer 's pathology .</brief_summary>
	<brief_title>A Non-drug Methods Study Participants With Alzheimer 's Disease</brief_title>
	<detailed_description>After trial initiation , protocol amend extend single observation time period ( 6 9 month ) two time point ( 6 12 month ) , focus prodromal AD ( Mini-Mental State Examination [ MMSE ] 23-30 inclusive , Free Cued Selective Reminding Test [ FCSRT ] less equal [ ≤ ] 24 free recall ≤ 44 total recall ) . Participants enrol original protocol allow continue extension study desire , meet new inclusion criterion . Due number participant complete extended trial , sub-group analysis perform base amendment participant enter .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Present prodromal Alzheimer 's Disease ( AD ) mild AD base disease diagnostic criterion Are men postmenopausal woman , least 55 year age . Postmenopausal woman define woman hysterectomy and/or bilateral oophorectomy ; amenorrheic least 2 year Have caretaker/study informant provide separate write informed consent participate . If caretaker/study informant continue , one replacement allow Gradual progressive change memory function report participant informant 6 month Objective evidence significantly impaired episodic memory characteristic hippocampal dysfunction testing : Free Cued Selective Reminding Test ( FCSRT ) : less equal ( ≤ ) 16 free recall ≤ 40 total recall . Protocol amendment : FCSRT ≤ 24 free recall ≤ 44 total recall Clinical Dementia Rating ( CDR ) equal 0.5 1 , Memory box score great equal 0.5 Mini Mental Scale Examination ( MMSE ) 2030 . Protocol amendment : MMSE 2330 , inclusive Positive florbetapir F 18 scan Participants must meet Disease Diagnostic Criteria consider enrollment Diagnosis history possible etiology dementia , include limited neurodegenerative disorder Frontotemporal dementia , Lewy body disease , vascular dementia , Huntington 's Disease concomitant Parkinson 's disease , progressive supranuclear palsy ( PSNP ) movement disorder Has B12 &lt; 200 pg/L folate &lt; 7.5 nmol/L indicate vitamin deficiency Has history within past 5 year serious infectious disease affect brain , include meningitis , encephalitis Significant history alcoholism substance abuse ( judgment investigator ) Severe recurrent head injury clinically relevant disease study , ( , permanent neurological/cognitive sequela ) Onset dementia follow heart surgery cardiac arrest Diagnosis history cerebrovascular disease ( example , stroke , transient ischemic attack ) , severe carotid stenosis , cerebral hemorrhage , intracranial tumor , subarachnoid hemorrhage , subdural hematoma could contribute subject 's current cognitive functional status , impair ability fully participate trial may impact status Has Positron Emission Tomography ( PET ) within 6 month schedule image followup Greater 4 cerebral microhemorrhages ( CMH ) T2* weight gradientrecalled echo sequence ( regardless anatomical diagnostic characterization `` possible '' `` definite '' ) , single area superficial siderosis , prior evidence macrohemorrhage Any indication severe deep white matter lesion vasogenic edema present hyperintense region Fluid Attenuated Inversion Recovery ( FLAIR ) sequence , clinically relevant finding observe Magnetic Resonance Imaging ( MRI ) scan Specific exclusionary brain MRI finding , determine investigator consultation sponsor , could either contribute participant 's current cognitive functional decline impair ability fully participate trial may impact status trial ( example , brain tumor nonvascular structural abnormality like hydrocephalus ) History within past 5 year primary recurrent malignant disease exception resect cutaneous squamous cell carcinoma situ , basal cell carcinoma , cervical carcinoma situ , situ prostate cancer normal prostatespecific antigen ( PSA ) post resection History clinically significant cardiovascular renal event Diastolic blood pressure 95 systolic blood pressure 160 sit position least 5 minute rest Any history seizure History clinically significant head trauma clinically significant unexplained loss consciousness within last 5 year ( determine investigator consultation Sponsor ) A current Axis I diagnosis major depressive disorder psychiatric illness ( Diagnostic Statistical Manual Revised Fourth Edition [ DSMIVTR ] ) criterion per investigator 's judgment . ( Note : Participants stable antidepressant and/or anxiolytic treatment may participate . ) Having suicidal ideation , attempt suicide past 15 year History schizophrenia , bipolar disorder , severe mental illness Known history alcohol drug abuse ( define DSMIVTR ) within 5 year prior enrol positive result regard use illicit drug drug screen test Chronic hepatic disease indicate liver function test abnormality ( alanine trasaminase [ ALT ] , aspartate transaminase [ AST ] , bilirubin , gammaglutamyl transferase [ GGT ] 2 time upper limit normal ) , positive serology Hepatitis B C , manifestation liver disease Has compromise renal function screening , determine creatinine clearance &lt; 30 mL/min base CockcroftGault calculation creatinine clearance History asthma , chronic obstructive pulmonary disease , chronic respiratory condition Known positive human immunodeficiency virus ( HIV ) status , history syphilitic infection A clinically significant abnormality 12lead electrocardiogram ( ECG ) , include complete heart block , bradycardia ( heart rate &lt; 50 beats/minute ) , tachycardia ( heart rate ≥95 beats/minute ) , sinus pause &gt; 2 second , second third degree heart block , QTc &gt; 450 msec male QTc &gt; 470 female Treatment investigational small molecule within 1 year precede first study period , participation trial active passive immunization amyloid participant assign active treatment arm Fulfillment contraindication 3T magnetic resonance imaging ( MRI ) scan ( example , subject nonremovable ferromagnetic implant ( cardiac pacemaker ) , aneurysm clip foreign body , subject claustrophobic symptom would contraindicate MRI scan ) Sensitivity florbetapir F 18 Are capable swallow whole oral medication Abnormal thyroid function Thyroid stimulate hormone ( TSH ) value outside normal range 0.35.6 mIU/L . ( NOTE : Participants stable treatment hypothyroidism normal value TSH allow enter study )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Brain Imaging Biomarkers</keyword>
	<keyword>Magnetic resonance imaging biomarker</keyword>
	<keyword>Positron Emission Tomography</keyword>
</DOC>